The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Boron-10     boron

Synonyms: AC1O3TG9, 14798-12-0, Boron, isotope of mass 10
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of boron

  • The application of boron neutron capture therapy to rheumatoid arthritis requires the selective delivery of the boron-10 isotope to the synovitic tissue [1].
  • Ion microscopy revealed a consistent pattern of boron-10 microdistribution for both rat brain tumor models [2].
  • One hour after a 2-h i.v. infusion of BPA in rats with the 9L gliosarcoma, tumor boron-10 concentrations were 2.7 times higher than that of infiltrating tumor cells [83 +/- 23 microg/g tissue versus 31 +/- 12 microg/g tissue (mean +/- SD)] [2].
  • In three cases, boron-10 was identified in glioblastoma cells by laser microprobe mass analysis [3].
  • The boron-10 concentration and the tumor:blood concentration ratio in large and medium-sized gliomas were adequate for successful BNCT [4].

High impact information on boron


Chemical compound and disease context of boron

  • Now the boron-10 glycineamide analog (A8), amineboryl-carboxamide has been synthesized; it contains 13.81% boron (90% Boron 10 + 10% Boron 11) and shows a very low toxicity in mice [10].

Biological context of boron

  • The biological effect of this thermalized component on cells "tagged" with boron-10 (10B) is modeled mathematically and the expected change in cell survival calculated [11].
  • The relative biological effectiveness (r.b.e.), expressed as the Do ratio, increased from 2.2 +/- 0.1 for the control without boron-10 to 5.4 +/- 0.3 in the medium containing 0.9 mM boron-10 [12].
  • The distribution of boron-10 also varied, correlating to capillary permeability [4].
  • To optimize the neutron dose for boron neutron capture therapy (BNCT), the boron-10 (10B) concentration kinetics of 10B-p-boronophenylalanine (BPA) were analysed in 22 melanoma patients with primary or metastatic melanomas who received BPA and subsequently underwent BNCT or surgery [13].
  • However, precise and accurate measurements of boron-10 concentrations (0.1-100 microg/g) in specimens and samples of limited size (microg scale) are needed in order to be able to biologically characterise new compounds in predictive tissue dosimetry, toxicology and pharmacology studies as well as in clinical investigations [14].

Anatomical context of boron

  • Three doses of BPA 700, 1000 and 1600 mg kg(-1) were used to establish the biodistribution of boron-10 (10B) in blood, spinal cord and brain over a 3-h period after intraperitoneal (i.p.) administration [15].
  • Analytical calculation of boron- 10 dosage in cell nucleus for neutron capture therapy [16].
  • The present study addressed whether inhibited spermiation can be separated from atrophy based on dose, compared testis boron (B) dosimetry to lesion development, determined how inhibited spermiation was reflected by common reproductive endpoints, and examined reversibility of the testicular lesions [17].
  • Calculated responses to a thermal neutron beam for hamster and HeLa cells containing boron-10 at different concentrations [18].
  • Our mathematical modeling predicts that BNCT enhancement of our beam will lead to an additional 1-2 logs of tumor cell kill for boron-10 concentrations of 30-50 micrograms/g. We have validated this via V-79 cell line in vitro measurements [19].

Associations of boron with other chemical compounds


Gene context of boron

  • RESULTS: Pharmacokinetic experiments: Six hours following administration of BPA, tumor, blood, and normal brain boron-10 levels were 23.7, 9.4, and 8.4 micrograms/g respectively [22].
  • Highly localized energy depositions come from Auger emitters such as 125I and by the neutron capture therapy, where boron-10 in the tumor cell is exposed to thermal neutrons for initiating the B10 (n; alpha) Li7 reaction, especially for treating neuro- and glioblastoma and melanoma [23].
  • The proposed concept would utilize a neutral nontoxic boron-10 predicting that anti HER-2 MABs would assure its selective delivery to cancer cells [24].
  • Third, we conducted combination treatment with 4.8 kGy of alpha-particles, i.e., boron 10 neutron captured beam induced by Kyoto University Research Nuclear Reactor operated at 5 MW, and hyperthermia at 52 degrees C, which caused the synergistic killing effect on D. radiodurans wet cells [25].
  • An Arabidopsis thaliana cDNA library was introduced into a Saccharomyces cerevisiae mutant that lacks ScBOR1 (YNL275W), a boron (B) efflux transporter [26].

Analytical, diagnostic and therapeutic context of boron

  • The successful treatment of cancer by boron neutron-capture therapy (BNCT) requires the selective concentration of boron-10 within malignant tumors [27].
  • The results show that the boron-conjugated antibodies retain selective localization in the tumors, thus indicating their suitability for transporting boron-10 to tumors for use in neutron-capture therapy of cancer [5].
  • These results are important for BNCT, because clinical protocols using a 2-h infusion have been performed with the assumption that infiltrating tumor cells contain equivalent amounts of boron-10 as the MTM [2].
  • Boronophenylalanine (BPA) is used as Boron-10 carrier in boron neutron capture therapy, an experimental cancer radiotherapy [28].
  • Dosimetric and radiobiological studies were undertaken to investigate the potential enhancement in dose, dose distribution and cell killing effectiveness of 252Cf brachytherapy achievable when boron-10 enriched compounds are incorporated into simulated 252Cf brain implants [29].


  1. Model studies directed toward the application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in rat collagen-induced arthritis. Watson-Clark, R.A., Banquerigo, M.L., Shelly, K., Hawthorne, M.F., Brahn, E. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  2. Quantitative imaging and microlocalization of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy: relevance to neutron capture therapy. Smith, D.R., Chandra, S., Barth, R.F., Yang, W., Joel, D.D., Coderre, J.A. Cancer Res. (2001) [Pubmed]
  3. Subcellular boron-10 localization in glioblastoma for boron neutron capture therapy with Na2B12H11SH. Haselsberger, K., Radner, H., Gössler, W., Schlagenhaufen, C., Pendl, G. J. Neurosurg. (1994) [Pubmed]
  4. Capillary permeability and boron distribution in ethylnitrosourea-induced rat glioma. Abe, M., Amano, K., Kitamura, K., Ohta, M., Tateishi, J., Hatanaka, H. Neurosurgery (1988) [Pubmed]
  5. Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system. Goldenberg, D.M., Sharkey, R.M., Primus, F.J., Mizusawa, E., Hawthorne, M.F. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  6. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Al-Madhoun, A.S., Johnsamuel, J., Barth, R.F., Tjarks, W., Eriksson, S. Cancer Res. (2004) [Pubmed]
  7. Boron neutron capture therapy of cancer: current status and future prospects. Barth, R.F., Coderre, J.A., Vicente, M.G., Blue, T.E. Clin. Cancer Res. (2005) [Pubmed]
  8. Boron microlocalization in oral mucosal tissue: implications for boron neutron capture therapy. Morris, G.M., Smith, D.R., Patel, H., Chandra, S., Morrison, G.H., Hopewell, J.W., Rezvani, M., Micca, P.L., Coderre, J.A. Br. J. Cancer (2000) [Pubmed]
  9. Comparison of radiation effects of gadolinium and boron neutron capture reactions. Tokuuye, K., Tokita, N., Akine, Y., Nakayama, H., Sakurai, Y., Kobayashi, T., Kanda, K. Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]. (2000) [Pubmed]
  10. Analytical techniques for boron and boron 10 analysis in a solid experimental tumor EO. 771. Porschen, W., Marx, J., Dallacker, F., Mückter, H., Böhmel, T., Fairchild, R., Feinendegen, L.E. Radiation and environmental biophysics. (1987) [Pubmed]
  11. Boron neutron capture therapy: a mechanism for achieving a concomitant tumor boost in fast neutron radiotherapy. Laramore, G.E., Wootton, P., Livesey, J.C., Wilbur, D.S., Risler, R., Phillips, M., Jacky, J., Buchholz, T.A., Griffin, T.W., Brossard, S. Int. J. Radiat. Oncol. Biol. Phys. (1994) [Pubmed]
  12. Lethal effect and potentially lethal damage recovery in cultured mammalian cells irradiated by neutron-capture beams. Maki, H. Int. J. Radiat. Biol. (1989) [Pubmed]
  13. Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. Fukuda, H., Honda, C., Wadabayashi, N., Kobayashi, T., Yoshino, K., Hiratsuka, J., Takahashi, J., Akaizawa, T., Abe, Y., Ichihashi, M., Mishima, Y. Melanoma Res. (1999) [Pubmed]
  14. Capillary electrophoresis-electrospray mass spectrometry and HR-ICP-MS for the detection and quantification of 10B-boronophenylalanine (10B-BPA) used in boron neutron capture therapy. Pitois, A., de las Heras, L.A., Zampolli, A., Menichetti, L., Carlos, R., Lazzerini, G., Cionini, L., Salvatori, P.A., Betti, M. Analytical and bioanalytical chemistry. (2006) [Pubmed]
  15. Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine. Morris, G.M., Coderre, J.A., Micca, P.L., Fisher, C.D., Capala, J., Hopewell, J.W. Br. J. Cancer (1997) [Pubmed]
  16. Analytical calculation of boron- 10 dosage in cell nucleus for neutron capture therapy. Kobayashi, T., Kanda, K. Radiat. Res. (1982) [Pubmed]
  17. Testicular toxicity of boric acid (BA): relationship of dose to lesion development and recovery in the F344 rat. Ku, W.W., Chapin, R.E., Wine, R.N., Gladen, B.C. Reprod. Toxicol. (1993) [Pubmed]
  18. Calculated responses to a thermal neutron beam for hamster and HeLa cells containing boron-10 at different concentrations. Saigusa, T., Ueno, Y. Physics in medicine and biology. (1978) [Pubmed]
  19. Enhancement of fast neutron beams with boron neutron capture therapy. A mechanism for achieving a selective, concomitant tumor boost. Buchholz, T.A., Laramore, G.E., Wootton, P., Livesey, J.C., Wilbur, D.S., Risler, R., Phillips, M., Jacky, J., Griffin, T.W. Acta oncologica (Stockholm, Sweden) (1994) [Pubmed]
  20. Dynamic SIMS ion microscopy imaging of intracellular boron accumulation from carboranyl nucleosides in glioma cells. Gay, I., Lorey, D.R., Schinazi, R.F., Morrison, G.H., Chandra, S. Anticancer Res. (2001) [Pubmed]
  21. Preparation and characterization of liposomal systems entrapping the boronated compound o-carboranylpropylamine. Moraes, A.M., Santana, M.H., Carbonell, R.G. Journal of microencapsulation. (1999) [Pubmed]
  22. A nude rat model for neutron capture therapy of human intracerebral melanoma. Barth, R.F., Matalka, K.Z., Bailey, M.Q., Staubus, A.E., Soloway, A.H., Moeschberger, M.L., Coderre, J.A., Rofstad, E.K. Int. J. Radiat. Oncol. Biol. Phys. (1994) [Pubmed]
  23. Contributions of nuclear medicine to the therapy of malignant tumors. Feinendegen, L.E. J. Cancer Res. Clin. Oncol. (1993) [Pubmed]
  24. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions. Mundy, D.W., Harb, W., Jevremovic, T. Physics in medicine and biology. (2006) [Pubmed]
  25. Synergistic cell-killing effect of a combination of hyperthermia and heavy ion beam irradiation: in expectation of a breakthrough in the treatment of refractory cancers (review). Imamura, M., Sawada, S., Kasahara-Imamura, M., Harima, K., Harada, K. Int. J. Mol. Med. (2002) [Pubmed]
  26. Isolation of Arabidopsis thaliana cDNAs that confer yeast boric acid tolerance. Nozawa, A., Miwa, K., Kobayashi, M., Fujiwara, T. Biosci. Biotechnol. Biochem. (2006) [Pubmed]
  27. Model studies directed toward the boron neutron-capture therapy of cancer: boron delivery to murine tumors with liposomes. Shelly, K., Feakes, D.A., Hawthorne, M.F., Schmidt, P.G., Krisch, T.A., Bauer, W.F. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  28. Optimized 1H MRS and MRSI methods for the in vivo detection of boronophenylalanine. Bendel, P., Margalit, R., Salomon, Y. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. (2005) [Pubmed]
  29. Boron neutron capture enhancement of 252Cf brachytherapy. Beach, J.L., Schroy, C.B., Ashtari, M., Harris, M.R., Maruyama, Y. Int. J. Radiat. Oncol. Biol. Phys. (1990) [Pubmed]
WikiGenes - Universities